24% Complete

The relationship between Iron and Prostate cancer is weak. Iron ranks 106 of 957 Prostate cancer treatments we have analyzed.

Prostate cancer, also known as carcinoma of the prostate, is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively fast. The cancer cells may spread from the prostate to other parts of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages it can cause difficulty urinating, blood in the urine, or pain in the pelvis, back or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.1

Iron is a chemical element with symbol Fe (from Latin: ferrum) and atomic number 26. It is a metal in the first transition series. It is by mass the most common element on Earth, forming much of Earth's outer and inner core. It is the fourth most common element in the Earth's crust. Its abundance in rocky planets like Earth is due to its abundant production by fusion in high-mass stars, where the production of nickel-56 (which decays to the most common isotope of iron) is the last nuclear fusion reaction that is exothermic. Consequently, radioactive nickel is the last element to be produced before the violent collapse of a supernova scatters precursor radionuclide of iron into space.2

Researchers have concluded:

  • USPIO-DW-MRI is a fast and accurate method for detecting pelvic lymph node metastases, even in normal-sized nodes of bladder or prostate cancer patients.3
  • To the best of our knowledge, this is the first study reporting direct in-vitro MnCl2 labelling and 7 T based in-vivo MRI tracing of cancer cells in a model of prostate cancer. MnCl2 labelling was found to be suitable for in-vivo tracing allowing long detection periods. The labelled cells kept their highly tumourigenic potential in-vivo. Tumour volume development was visualised prior to manual palpation allowing tumour characterisation in early stages of the disease.4
  • Enhancement of the prostate gland after USPIO administration may be associated with primary prostate cancer.5
  • Only PSMA-targeted SPMs and paclitaxel significantly prevented growth of C4-2 prostate cancer xenografts in nude mice. Furthermore, mice injected with PSMA-targeted SPMs showed significantly more paclitaxel and platinum in tumors, compared with nontargeted SPM-injected and paclitaxel-injected mice.6
  • Since prostate cancer bone metastatic patients have high β2-M in the tumor tissue and in the secreted form, targeting β2-M with anti-β2-M Ab is a promising therapeutic agent. Additionally, inhibition of β2-M sensitizes cancer cells to clinically used therapies such as radiation by inducing iron overload and decreasing DNA repair enzymes.7

Review all research »

Strength of evidence

Iron for Prostate cancer ranks in the bottom 24% of condition-treatment relationships we analyzed.

Importantly, we found only 1 study that was randomized and controlled. Such studies are considered the most rigorous, and help to establish or disprove a cause-and-effect relationship between prospective treatments and conditions. So there may be some good evidence on which to make a decision about using Iron for Prostate cancer.

Amount of research

The relationship between Prostate cancer and Iron has been modestly researched. We found 155 research articles on the topic. This places the volume of research in the bottom 25% of condition-treatment relationships we have analyzed.

Research trends

Are researchers becoming more or less interested in Iron for Prostate cancer? The pace of research appears to be increasing.

Registered clinical trials

We found no registered clinical trials investigating Iron for Prostate cancer.

Important caveat—help improve this information

Please note that our analysis is automated and imperfect. If you have personal insight, please help improve our analysis by rating this relationship and the research supporting it. And check back regularly; we last analyzed research for this relationship on September 06, 2014 @9:46PM, and are constantly updating our database and algorithms.

Other names
Iron for Prostate cancer is also known as 7439-89-6 for Androgen Independent, 7439-89-6 for Cancer of the prostate, 7439-89-6 for Cancer prostatae, 7439-89-6 for Castrate-Resistant, 7439-89-6 for Castration-resistant prostate cancer, 7439-89-6 for Hormone.

Top treatments for Prostate cancer

98% Complete
97% Complete
96% Complete
96% Complete
95% Complete
94% Complete
92% Complete
92% Complete
92% Complete
91% Complete